Description
Anti-Obesity Drug-9604 (AOD-9604) is indeed a synthetic peptide derived from a segment of the human growth hormone (GH) molecule. Specifically, it corresponds to a region of GH that includes amino acids 176-191. This peptide fragment is known for its ability to mimic the lipolytic (fat-burning) properties of GH, but with several distinct advantages:
- Fat-Burning Effects: AOD-9604 promotes fat breakdown (lipolysis) and inhibits fat accumulation in the body. This mechanism is similar to GH, which also stimulates lipolysis, but AOD-9604 has been reported to be more specific and potent in targeting fat cells.
- No Impact on Blood Glucose Levels: Unlike full-length GH, which can affect insulin sensitivity and blood glucose levels, AOD-9604 does not exert these effects. This makes it potentially safer for individuals concerned about glucose metabolism.
- No Impact on Growth: AOD-9604 lacks the growth-promoting effects of GH, focusing solely on fat metabolism. This specificity makes it suitable for use in adults looking to reduce body fat without affecting other aspects of metabolism or growth.
- Research and Development: While AOD-9604 has shown promise in preclinical and early clinical studies for obesity treatment, its regulatory status and availability vary by region. It continues to be investigated for its potential therapeutic applications in combating obesity and related metabolic disorders.
How It Works
AOD-9604, derived from a segment of the human growth hormone (GH), indeed offers several unique benefits in promoting fat metabolism:
- Promotes Lipolysis: AOD-9604 enhances the breakdown of stored fat (lipolysis) by stimulating the release of fatty acids from adipose tissue. This process helps in reducing body fat levels.
- Prevents Lipogenesis: It inhibits the formation of new fat cells (lipogenesis), thereby preventing the accumulation of fat in the body.
- No Effect on Hunger: Unlike some growth hormone treatments that can increase appetite, AOD-9604 does not stimulate hunger. This property is beneficial for weight management as it does not lead to increased caloric intake.
- No Impact on Blood Sugar Levels: AOD-9604 does not affect blood glucose levels or insulin sensitivity. This characteristic makes it potentially safer for individuals with concerns about glucose metabolism.
- No Tissue Growth Effects: Unlike full-length GH, which can promote tissue growth including muscle and bone, AOD-9604 specifically targets fat cells without affecting other tissues. This specificity is advantageous for individuals focused solely on fat reduction.
- Independent of hGH Receptor: AOD-9604 exerts its effects independently of the growth hormone receptor on the pituitary gland. This means it does not interfere with the natural production and regulation of growth hormone in the body.
Research Benefits
AOD-9604, derived from human growth hormone, exhibits several beneficial effects related to fat metabolism and overall metabolic regulation:
- Stimulates Lipolysis: AOD-9604 promotes the breakdown of stored fat (lipolysis) by enhancing the release of fatty acids from adipose tissue. This helps in reducing body fat levels.
- Inhibits Lipogenesis: It prevents the formation of new fat cells (lipogenesis), thereby limiting the accumulation of fat in the body.
- Boosts Metabolism: By enhancing lipolysis and reducing fat accumulation, AOD-9604 can contribute to an overall increase in metabolic rate. This can potentially aid in burning more calories even at rest.
- Reduces Abdominal Fat: AOD-9604 specifically targets visceral fat, including abdominal fat, which is associated with increased health risks such as cardiovascular disease and diabetes.
- Promotes Muscle Growth: While primarily known for its effects on fat metabolism, AOD-9604 may also have indirect benefits for muscle growth. By reducing fat mass, it can enhance muscle definition and improve body composition.
- Helps Regulate Blood Sugar Levels: AOD-9604 does not significantly impact blood glucose levels or insulin sensitivity, making it a safer option for individuals concerned about metabolic health and diabetes risk.
Additional Info
Properties
- Chemical Formula: C78H123N23O23S2
- Molecular Mass: 1815.12 g/mol
- Synonyms: AOD-9604, AOD 9604, AOD9604
- CAS Number: 221231-10-3
- PubChem: 16131447
- Total Amount of Active Ingredient: 5 mg (1 vial)
- Shelf Life: 36 months
Shipping
For international orders, if your shipment is seized, we will offer a 50% discount on your next purchase. Please contact us for more details.
Disclaimer
The information provided does not replace medical advice, diagnosis, or treatment. If you have any medical questions, consult your physician or a qualified healthcare provider. Never disregard or delay seeking medical advice based on what you have read. We are not responsible for any use of our research compounds and products. These are sold strictly for research purposes only and are not approved for personal use.
Additional Label and Product Information
Essential Warning:
The chemicals are intended solely for research or laboratory use and are not approved by the FDA for human consumption.
Using Instructions:
- Avoid skin and eye contact. If contact occurs, rinse immediately with plenty of water.
- Seek medical advice if you feel unwell or in case of accidental ingestion.
- Store the lyophilized (freeze-dried) peptide at room temperature upon receipt.
- Avoid frequent freeze-thaw cycles to maintain peptide stability.
Product Disclaimer
This product is not intended to diagnose, treat, cure, or prevent any disease. Use only as specified by your research or laboratory protocol.
Resources
- Ng, F. M., et al. (2000). Metabolic investigations of a synthetic lipolytic domain (AOD 9604) derived from human growth hormone. Hormone Research, 53(6), 274–278. DOI
- Cox, H. D., et al. (2015). Identification and in vitro breakdown of AOD 9604. Drug Testing and Analysis, 7(1), 31–38. DOI
- Ng, F. M., et al. (2000). Molecular and cellular actions of a structural segment of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology, 25(3), 287-298.
- Heffernan, M. A., et al. (2001). Enhancement of fat oxidation and weight loss in obese mice through prolonged treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders, 25(10), 1442–1449. DOI
- Ng, F. M., et al. (2000). Metabolic assessments of a synthetic lipolytic domain (AOD9604) derived from human growth hormone. Hormone Research, 53(6), 274–278. DOI
- Kopchick, J. J., et al. (2020). Effects of growth hormone on adipose tissue: historical observations and novel mechanisms. Nature Reviews Endocrinology, 16(3), 135-146.
- Heffernan, M., et al. (2001). Impact of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following prolonged treatment in obese mice and β3-AR knockout mice. Endocrinology, 142(12), 5182-5189.
- Bray, G. A., & Greenway, F. L. (2007). Pharmacotherapy for overweight patients. Pharmacological Reviews, 59(2), 151–184. DOI
- Heffernan, M., et al. (2001). Effects of human GH and its lipolytic fragment (AOD 9604) on lipid metabolism following prolonged treatment in obese mice and beta(3)-AR knockout mice. Endocrinology, 142(12), 5182–5189. DOI
- Kwon, D. R., & Park, G. Y. (2015). Impact of intra-articular injection of AOD 9604 with or without hyaluronic acid in a rabbit model of osteoarthritis. Annals of Clinical and Laboratory Science, 45(4), 426–432.
Reviews
There are no reviews yet.